Evidence map›Paper›PMID 40599499›Full record

ArticleCureus2025

Giant Prolactin-Secreting Pituitary Adenoma: A Case Report and Literature Review.

Jorge A Ocon Rodríguez, Angélica López Méndez, Emilio Mondragón Rosas, Airam A Arias Villaverde, Elizabeth Gloria Méndez, Michelle Cruz Méndez, Lourdes Rivas Ayala, José Emiliano González Flores

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jorge A Ocon RodríguezNeurosurgery, Legaria Pediatric Hospital and General Hospital of Mexico, Mexico City, MEX.
Angélica López MéndezPediatric Nephrology, Legaria Pediatric Hospital and National Institute of Pediatrics, Mexico City, MEX.
Emilio Mondragón RosasMedicine and Health Sciences, Tecnológico de Monterrey Mexico City Campus, Mexico City, MEX.
Airam A Arias VillaverdeMedicine and Health Sciences, Tecnológico de Monterrey Mexico City Campus, Mexico City, MEX.
Elizabeth Gloria MéndezPediatrics, Panamerican University, Mexico City, MEX.
Michelle Cruz MéndezMedicine, Tecnológico de Monterrey Mexico City Campus, Mexico City, MEX.
Lourdes Rivas AyalaMedicine, Tecnológico de Monterrey Mexico City Campus, Mexico City, MEX.
José Emiliano González FloresMedicine and Health Sciences, Tecnológico de Monterrey Mexico City Campus, Mexico City, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolactinomas are the most common functional pituitary adenomas in the pediatric population, though they remain rare overall. Male adolescents often present with larger and more aggressive tumors than female adolescents, with delayed symptoms such as visual disturbances, headaches, and hypogonadism due to the absence of early hormonal signs. We report the case of a 15-year-old previously healthy male patient who presented with a one-month history of severe frontal headache, followed by blurred vision and vomiting. On examination, he exhibited bilateral mydriatic pupils unresponsive to light, left eye outward deviation, ataxic gait, and asthenic appearance. Brain MRI revealed a large sellar mass suggestive of an invasive pituitary adenoma. Laboratory evaluation showed extreme hyperprolactinemia (50,260.9 ng/mL) and central hypothyroidism, leading to the diagnosis of a giant invasive prolactinoma. He was treated with cabergoline and levothyroxine. Due to neuropsychiatric symptoms (hallucinations, insomnia, and agitation), aripiprazole and melatonin were added. No evidence of apoplexy or intracranial hypertension was found. Craniotomy surgery was performed successfully. Clinical improvement was observed, but the patient was lost to follow-up. This case illustrates the classical presentation of giant prolactinoma in a male adolescent, emphasizing the size-prolactin correlation and the importance of early detection and medical treatment. Neuropsychiatric symptoms can emerge as a result of tumor mass effect or dopaminergic therapy. Long-term follow-up is essential to evaluate treatment response and prevent endocrine and developmental complications. Genetic testing for MEN1 or AIP mutations should be considered in young patients with aggressive pituitary adenomas.

Indexed as

cabergoline resistancecraniotomydopamine agonistshyperprolactinemiamen1 mutationpituitary neoplasmsprolactinoma

Identifiers

PMID40599499
PMCPMC12208814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.